Browse drugs

… promoted tumour growth, with significant tumour restriction on atorvastatin pre-exposure. CCR7 low, CD40low, CD80 low, CD86 lowPDL1high FAS…

…s introduced, initially referring to TB resistant to isoniazid, rifampicin, and at least three of the six main classes of second line drug…

…f the original trial (3.3 years), all participants were offered atorvastatin. Lipid profiles were obtained from all subjects 2 years later a…

…essment for insulin resistance (HOMA-IR) among PWH treated with rosuvastatin vs. atorvastatin. The secondary objectives were to evaluate bas…

…, coupled with rapid clinical and biochemical improvement after atorvastatin discontinuation, supported a diagnosis of rhabdomyolysis due to…

…tin decision-making process significantly improved adherence to atorvastatin therapy and reduced certain perceived side effects. This approa…

…n and expenditure in statin was contributed by atorvastatin and rosuvastatin. After the NVBP policy, the utilisation of atorvastatin and ros…

….87 for distinguishing progression patterns ( figure 1). In the atorvastatin arm, a distinct autoantibody profile comprising eight autoantib…

…arget (111) Off target (197) Both groups (308) Statin% 95 85 89 Atorvastatin Total Number% 62 61 62 Mean Dose (mg) 57.71 (SD 25.03) 58.33 (S…

…CD16+/CD137+) at 1 week after the first infusion, regardless of W0180 dose (online supplemental figure S7).Of the pro-inflammatory cy…

…006, random effects model), covering various statins, including atorvastatin, simvastatin, rosuvastatin, fluvastatin, pitavastatin, pravasta…

…vastatin/rosuvastatin) statins; (2A) P-glycoprotein inhibitors (simvastatin/atorvastatin) versus non-inhibitors (pravastatin) in patients p…